The head-to-head deck your MASH trial team has been asking for.

A focused competitive read for sponsors evaluating central pathology for MASH trials. The integrated platform difference (LiverMultiScan plus PAIR-MASH versus AIM-MASH pathology-only), central-read capability, an honest regulatory status table, and the combined-modality claim Path.AI cannot make.

Updated quarterly. Sent privately to every sponsor team evaluating AIM-MASH on a Phase 2/3 MASH programme. A separate PAIR-IBD vs AIM-HI UC deck follows once the PAIR-IBD launch is sequenced.

Four arguments, evidence-first, every claim sourced.

Built to be read by a Phase 2b biomarker lead, a regulatory affairs partner, and an imaging committee chair in the same hour. No marketing language without an evidence line behind it.

01 · Pillar

Imaging heritage as the differentiator.

Path.AI reads pathology. Perspectum reads the disease system: MRI, pathology, and trial operations in one quantitative evidence platform, with digital endoscopy on the roadmap. The pitch Path.AI cannot make.

02 · Pillar

Central read your IDMC will accept.

Slide to digitised report inside 48 hours. Geboes histopathology and an anatomy-anchored scoring stack underneath, audit-ready and reviewer-panel transparent. Digital endoscopy, with UCEIS and Mayo scoring, on the roadmap.

03 · Pillar

Regulatory roadmap, named and dated.

FDA DDT-COA in preparation, EMA pre-engagement, MHRA SaMD pathway opened. Honest on what is submitted, accepted, or pending, not a category claim.

04 · Pillar

Combined-modality claim.

LiverMultiScan + PAIR-MASH as a programme-wide trial-acceleration platform. Pending the highest-leverage publication of the next 24 months, but the claim Path.AI cannot make at any time.

The honest side-by-side that holds up in slide three.

A condensed view of the comparative table the gated deck carries. Detailed regulatory status descriptors are in the deck itself.

Dimension	PAIR-MASH (LiverMultiScan + AI pathology)	Path.AI AIM-MASH
Modality coverage	AI pathology + quantitative MRI (cT1, PDFF)	AI-pathology only
MASH trial experience	10+ Phase 3 MASH trials supported through Perspectum central reading	Multiple Phase 3 MASH programmes under AIM-MASH
Pathology evidence stack	20+ pathology-focused publications spanning peer-reviewed journals and conference abstracts	Multi-year slide-level annotation and validation programme
Regulatory status (honest)	PAIR-MASH: DDT-COA submission in preparation, EMA pre-engagement, MHRA SaMD pathway	AIM-MASH: FDA biomarker qualification, December 2025; EMA CHMP prior qualification
Combined-modality claim	LiverMultiScan + PAIR-MASH as a programme-wide MASH platform through one vendor	Pathology-only; imaging-modality claim not available
Trial-operations integration	Imaging-CRO operational stack and central-read infrastructure in one vendor relationship	Pathology central-read inside AISight Clinical Trials platform
Turnaround	Three-day sample processing; ten business days from receipt of tissue to delivered report	Comparable, vendor-published baseline
Imaging heritage	14 years of quantitative MRI; 100+ peer-reviewed publications; NAE-elected Co-founder	Pathology-AI heritage; imaging-modality claim not available

Last reviewed May 2026. Every cell in the full deck carries an evidence source, regulatory status descriptor, and review date, in line with the Perspectum claims matrix. Comparative claims are governed by Legal in partnership with Regulatory Affairs and Translational Science.

The full version, on request.

Sent privately to named sponsor evaluators within one working day. The deck includes the full comparative table with regulatory status descriptors, the named submission roadmap, evidence sources per pillar, and a pricing and contracting comparison where credible.

Under the Perspectum claims governance regime, the deck is updated quarterly. If you've received an earlier version, the next refresh is dated on the cover page; let us know and we'll send the current revision in the same response.